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Abstract  CT-guided  transparietal  lung  biopsy  in  imaging  makes  it  possible  to  ﬁnd  the
pathogenic  agent  in  half  of  all  fungal  infections  and  most  bacterial  infections  (sensitivity  =  55%,
speciﬁcity  =  100%).  Performance  is  decreased  in  consolidations  (50%  of  infections)  compared  to
masses. Complications,  pneumothorax,  alveolar  bleeding  and  hemoptysis  are  generally  benign
and rarely  (<  5%)  require  speciﬁc  treatment.  On  the  other  hand,  the  diagnostic  performanceLung  biopsy;
Infections
increases  signiﬁcantly  with  the  calibre  of  18G  co-axial  systems  compared  to  20G.  The  risk  is  not
related to  the  number  of  samples  or  platelet  levels.
© 2013  Éditions  françaises  de  radiologie.  Published  by  Elsevier  Masson  SAS.  All  rights  reserved.
The  prognosis  of  patients  being  treated  for  haematological  malignancies  has  clearly
improved  over  the  past  decades.  However,  these  patients  develop  numerous  complications
including  relapse  or  a  transformation  of  their  haemopathy,  a  primary  cancer,  tox-
icity  to  treatments  and  infection.  Haematological  malignancies  are  often  the  cause
of  an  immune  deﬁciency  that  promotes  the  onset  of  pulmonary  infections.  This
immune  deﬁciency  can  be  related  to  the  tumoural  disease  of  the  patient  or  to  the
treatments  he  or  she  receives.  Chemotherapies  are  responsible  for  variable  haema-
tological  toxicities  in  terms  of  depth  and  duration.  The  risks  of  infection  depend
on  the  type  of  immune  depression  induced  by  the  treatment  and  condition  the
risks  of  infection.  Short-term  neutropoenia  therefore  promotes  infections  caused  by
Gram-negative  bacilli  or  Gram-positive  cocci  while  long-term  neutropoenia  (acute
leukaemia,  chemotherapy)  creates  a  receptive  environment  for  fungal  infections  caused
by  Candida  or  Aspergillus. Cases  of  T  lymphocytopenia  observed,  for  example  in
∗ Corresponding author.
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pCT-guided  biopsies  in  lung  infections  
patients  with  lymphoma  or  leukaemia,  are  responsi-
ble  for  a  cell  immune  deﬁciency,  which  makes  these
patients  more  sensitive  to  viral  infections  (HSV,  EBV,
CMV,  etc.),  intracellular  bacterial  infections  (mycobac-
teria,  Nocardia,  Legionnella) and  intracellular  mycoses
(pneumocystosis,  toxoplasmosis,  etc.).  Humoral  deﬁcien-
cies  related  to  cases  of  B  lymphocytopenia  are  observed
in  patients  with  myeloma,  Waldenström’s  macroglobuli-
naemia,  chronic  lymphoid  leukaemia  and  chemotherapy
promote  intracellular  bacterial  and  viral  infections  and
encapsulated  bacterial  infections  (Staphylococcus  pneumo-
niae,  Haemophilus  inﬂuenzae, Staphylococcus  aureus).
Hospital-acquired  infections  can  also  occur,  such  as,
for  example,  septic  embolisms  originating  from  central
catheters  (S.  aureus, Pneudomonas  aeruginosa  or  Candida)
or  aspiration  pneumonia  from  mucitis  or  gastritis  that
promotes  the  colonisation  of  the  oro-pharynx  by  Gram-
negative  bacilli  (P.  aeruginosa, Enterobacter, Klebsiella,
Escherichia  coli  and  Acinetobacter)  [1].  Finally,  certain  non
infectious  lung  diseases  can  be  distinguished  from  infec-
tious  lung  diseases:  tumoural  progression,  the  onset  of  a
broncho-pulmonary  cancer,  pulmonary  infarction  (septic  or
cruoric  embolisms),  acute  pulmonary  oedema  (cardiotoxi-
city  of  chemotherapy,  overload),  alveolar  bleeding  due  to
thrombocytopenia  (allograft,  chemotherapy,  bone  marrow
insufﬁciency,  etc.),  diffuse  alveolar  damage  (severe  sepsis,
toxicity)  and  alveolar  proteinosis  that  promotes  infections
caused  by  Nocardia  (myelodysplasia,  immunoglobulin  deﬁ-
ciency).  Finally,  lesions  related  to  radiation  (consolidation,
organised  lung  disease)  or  drug-induced  toxicity  must  also  be
considered.  The  time  between  complications  and  treatment
is  important  data  to  be  taken  into  account  [2].  Therefore,
during  the  neutropoenia  of  the  ﬁrst  month,  bacterial  and
fungal  infections  (aspergillosis,  candidiasis)  will  be  encoun-
tered  more  frequently.  Then,  during  the  ﬁrst  3  months,
pneumocystosis  and  tuberculosis  should  be  screened  for.
Patients  can  then  develop  tuberculosis,  bacterial  infections
(S.  pneumoniae, H.  inﬂuenza),  viral  infections  (VZV)  that
must  be  distinguished  from  interstitial  pneumonia,  obliter-
ating  bronchiolitis  lesions  and  malignant  lesions.  In  the  same
way,  a  prolonged  corticosteroid  treatment  for  more  than
3  weeks  during  the  last  2  months  is  a  factor  that  promotes
aspergillosis.
The  high  resolution  scan,  the  clinical  data  and  the  lab-
oratory  samples  (blood  samples,  broncho-alveolar  lavage,
transbronchial  biopsies)  make  it  possible  to  obtain  the  aeti-
ological  diagnosis  of  the  pneumopathy  in  more  than  70%  of
cases.  On  the  other  hand,  for  the  remaining  patients,  the
scan  images  are  not  speciﬁc,  the  test  treatments  are  inef-
fective  and  the  samples  turn  out  to  be  sterile  or  inconclusive
(Fig.  1).  In  addition,  several  complications  can  develop  at
the  same  time  and  must  be  recognized.  For  these  patients,
percutaneous  lung  biopsy  (PLB)  guided  using  a  scan  is  an
absolutely  necessary  diagnostic  tool.  Since  1976,  many  pub-
lications  have  shown  that  PLB  is  a  simple  and  effective
technique  [3—10]. It  makes  it  possible  to  screen  for  infec-
tious  lung  disease  and  to  rule  out  other  diagnoses.  However,
the  use  of  PLB  is  often  impeded  by  the  fragile  condi-
tion  of  the  patients,  who  often  have  haemostasis  disorders
(thrombocytopenia,  anticoagulant  treatment).  In  the  same
way,  the  respiratory  ‘‘reserve’’  of  these  patients  is  often
limited  due  to  underlying  parenchymatous  lesions  (sequela
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f radiotherapy,  infections,  drug  toxicity)  and  the  onset  of
neumothorax  during  or  after  the  biopsy  can  considerably
orsen  respiratory  insufﬁciency.
The  objective  of  this  review  is  to  present  the  important
echnical  points  that  could  improve  the  performance  of  PLB
y  limiting  the  risk  of  complications.
reparation of the patient
T-guided  punctures  are  carried  out  under  local  anaesthe-
ia.  First,  it  is  absolutely  necessary  to  explain  to  the  patient
hat  is  at  stake  with  the  biopsy,  while  insisting  on  his  or
er  role  and  the  importance  of  his  or  her  cooperation.  It  is
lso  recommended  to  have  the  patient  sign  an  informed  con-
ent  form  after  having  given  him  or  her  fair  and  appropriate
xplanations.  The  fasting  condition  of  patients  is  controver-
ial.  If  there  is  an  exceptional  haemorrhagic  complication,
t  makes  easier  surgical  or  resuscitation  treatment  possible.
owever,  it  promotes  the  onset  of  vasovagal  syncope,  or
ypoglycaemia  in  diabetic  patients,  much  more  frequently.
n  approach  via  the  venous  route  is  absolutely  necessary  for
ung  biopsies.  It  is  exceptionally  used  due  to  uncontrolled
leeding,  but  it  can  be  very  useful  in  cases  of  pain  or  vaso-
agal  syncope.  An  emergency  cart  or  an  oxygen  tank  must
e  rapidly  accessible  in  order  to  be  able  to  carry  out  emer-
ency  ﬁrst  aid.  In  the  same  way,  a  monitoring  system  for
aturation  and  blood  pressure  and  a  scope  must  be  close  at
and.
Haemostasis  can  be  controlled  using  different  tests:
he  prothrombin  time  (PT)  calculated  using  the  Quick
ime  (QT)  and  the  International  Normalized  Ratio  [INR],
QTpatient/QTControl) make  it  possible  to  control  the  extrinsic
oute  of  coagulation  (factors  II,  V,  VII  and  X).  PT  is  reduced
n  patients  being  treated  with  vitamin  K  antagonists  or  those
ith  hepatocellular  insufﬁciency  or  DIC.  The  PT  is  normally
etween  70  and  100%.  Normal  INR  values  are  between  0.8
nd  1.2.  The  INR  must  be  systematically  checked  before  con-
ucting  a  lung  biopsy  and  corrected  if  it  exceeds  1.5  [11].
he  PTT  (partial  thromboplastin  time)  explores  the  intrin-
ic  route  of  coagulation  (factors  VIII,  IX,  XI  and  XII),  which
s  increased  in  patients  being  treated  with  heparin,  vita-
in  K  antagonists,  circulating  antiphospholipid  antibodies
lupus)  or  those  with  hepatocellular  insufﬁciency,  DIC,  von
illebrand  disease  and  haemophilia.  The  PTT  must  be  mea-
ured  in  all  of  these  clinical  situations.  A  normal  PTT  varies
etween  25  and  39  s.  The  PTT  ratio  (PTT  patient/PTT  con-
rol)  must  be  less  than  1.2.  On  the  other  hand,  there  is  no
onsensus  on  systematic  use  of  PTT  [11]. Fibrinogen  (fac-
or  I)  increases  in  cases  of  infection  or  inﬂammation  and
ecreases  in  cases  of  DIC.  In  risky  situations,  it  must  be
easured,  and  its  concentration  should  be  between  1.8  and
 g/L.  Platelet  levels  must  be  controlled  routinely  before
onducting  a  biopsy  in  this  at  risk  population  and  corrected
y  transfusion  if  the  levels  are  below  50,000/l.  Treatments
ith  Plavix  and  aspirin  must  be  suspended  5  days  before  the
rocedure.  Low  molecular  weight  heparins  must  be  stopped
4  h  ahead  of  time.
There  are  no  recommendations  concerning  respiratory
unction,  which  is  the  framework  for  the  PLB.  However,
ost  practitioners  recommend  not  biopsying  patients  with
204  C.  de  Bazelaire  et  al.
Figure 1. CT-scans in high diagnostic resolution (a, b and c) and CT-guided scan of percutaneous lung biopsies (d, e and f) in three
patients treated for haematological malignancies. The poorly delimited, spiculated, consolidating mass-type lesions are not speciﬁc. The
percutaneous biopsies found tuberculosis (a and d), mucormycosis (b and e) and MALT lymphoma (c and f).
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a  maximum  expiratory  volume  per  second  of  less  than  one
litre.
Diagnostic hypotheses
Interventional  radiologists  and  clinical  practitioners  must
discuss  the  diagnostic  hypotheses  before  the  procedure  and
deﬁne  the  diagnoses  to  be  screened  for  ﬁrst  in  order  to  limit
the  number  of  samples  to  be  taken.  The  conditioning  of  the
samples  must  be  suited  to  the  diagnostic  hypotheses.  Three
types  of  conditioning  are  predominant:  ﬁxation  in  all  cases,
freezing  in  case  of  a  suspected  solid  cancer  or  haemopathy
and  fresh  samples  to  screen  for  bacterial,  viral  or  fungal
infections  (Fig.  2).
Fixation
Fixed  samples  allow  for  morphological  (histological)  and
immunohistochemical  study.  The  biopsy  fragments  must  be
immediately  immerged  in  a  ﬁxating  liquid  such  as  10%
buffered  formaldehyde  or  a  mix  of  alcohol,  formaldehyde
and  acetic  acid.  They  are  then  sent  to  the  anatomical
pathology  lab.  The  immunohistochemistry  makes  it  possi-
ble,  thanks  to  the  use  of  monoclonal  antibodies,  to  detect
membrane  antigens  (ex:  CD20  marker  for  B  lymphocytes),
cytoplasm  antigens  (ex:  CD79a)  or  nuclear  antigens  (ex:
P53,  cyclin  D1  or  Ki67).  Immunohistochemical  studies  can  be
carried  out  on  ﬁxed  or  frozen  samples.  They  have  a  prepon-
derant  role  for  the  diagnosis  and  treatment,  as  they  make
o
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Figure 2. The conditioning of the samples must be suited to the dia
ﬁxation in all cases, freezing if there is a suspected solid cancer or hae
infections.205
t possible  to  prescribe  targeted  treatments  for  which  the
fﬁcacy  has  been  proven.
reezing
ften,  the  samples  are  put  on  a  compress  soaked  in  nor-
al  saline  and  rapidly  sent  to  the  anatomical  pathology  lab
here  they  are  frozen.  There  are  two  disadvantages:
the  time  for  transfer  to  the  laboratory  is  variable;
this  conditions  the  time  the  biopsy  is  carried  out.
We  recommend  direct  freezing  in  the  radiology  depart-
ent.  The  sample  must  be  frozen  quickly,  as  the  half-life  of
NA  is  10  min  under  the  effect  of  RNAases.  Each  biopsy  core
s  placed  on  a thin  sterile  slide  made  of  transparent  plas-
ic,  then  inserted  into  an  identiﬁed  tube.  Then,  this  tube  is
laced  in  a  canister  and  immerged  in  a  tank  of  nitrogen  at
80 ◦C.  Freezing  is  immediate.
Freezing  makes  it  possible  to  conduct  molecular  biol-
gy  analyses.  They  are  useful  for  determining  the  type  of
ymphoma:  screening  for  Bcl2  transcription  (B  lymphoma),
cl1  (mantle  cell  lymphoma)  or  Alk  (anaplastic  lymphoma).
creening  for  B  or  T  clonality  is  also  possible.  The  new  meth-
ds  of  molecular  biology  by  microarray  applied  to  human
issues  (DNA  array,  proteomic  and  protein  array,  CGH  array,
issue  microarray,  etc.)  theoretically  make  it possible  to
dentify  several  thousand  biological  markers  on  the  scale
f  the  genome,  transcriptome  and  proteome.  These  frozen
ores  are  also  a  reserve  to  complete  the  examinations  when
orphology  and  immunohistochemistry  turn  out  to  be  insuf-
cient.  In  the  same  way,  it  is  possible  to  resuscitate  bacteria
gnostic hypotheses. Three types of conditions are predominant:
mopathy and fresh samples to screen for fungal, viral or bacterial
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sing  frozen  samples  when  cultures  turn  out  to  be  insufﬁ-
ient  for  diagnosis.
resh samples
he  obtaining  of  fresh  samples  is  reserved  in  particular  for
creening  for  pathogenic  agents.  The  two  key  points  are  the
se  of  sterile  tubes  and  a  time  of  transfer  to  the  labora-
ory  that  is  as  short  as  possible.  The  samples  for  virological
tudy  are  rarely  taken  and  must  be  interpreted  along  with
he  markers  for  blood  replication.  If  there  is  a  risk  of  late
ransfer  of  the  sample  (laboratory  far  away  from  the  samp-
ing  site),  it  is  possible  to  use  speciﬁc  viral  transport  media.
hen,  the  identiﬁcation  of  the  different  viruses  is  carried
ut  after  grinding  of  the  sample  by  cell  culture  or  by  iden-
iﬁcation  of  nucleic  acids  in  molecular  biology.
ppositions
n  emergency  situations,  it  is  possible  to  carry  out  apposi-
ions.  A  core  sample  is  placed  directly  on  a  slide,  rolled,  and
hen  removed  before  being  ﬁxed.  The  cells  located  at  the
urface  of  the  core  sample  are  transferred  to  the  slide  and
eave  an  imprint  of  the  tissue  like  a  stamp  would  after  ink-
ng.  It  is  therefore  a  cytological  study  with  a  certain  degree
f  information  concerning  the  tissue  architecture.
hoice of the target thoracic  CT-scan  must  be  carried  out  before  every  biopsy.
his  examination  makes  it  possible  to  direct  the  ﬁbroscopy,
hus  improving  its  performance.  The  scan  can  also  show
eripheral  lesions  that  are  inaccessible  by  ﬁbroscopy  and
a
a
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igure 3. High resolution CT-scans. a: the biopsy made it possible to
reated for non-Hodgkin’s lymphoma; b: discovery of an adenocarcinoma
or non-Hodgkin’s lymphoma. The diagnostic performance of the biopsy
ower than for the mass of the patient in (b). The risk of pneumothorax i
rom the pleural cavity. On the other hand, the risk of complications is tC.  de  Bazelaire  et  al.
an  encourage  the  clinical  practitioner  to  do  a  PLB  directly.
n  the  other  hand,  the  scan  can  ﬁnd  diffuse  consolidations
r  areas  with  a  ground-glass  appearance  that  are  better
nalysed  by  bronco-alveolar  lavage  than  by  biopsy.  There
hould  be  no  hesitation  with  regard  to  repeating  the  tho-
acic  CT-scan  and  discussing  the  indication  of  the  PLB  again
f  the  clinical  course  of  the  patient  makes  it  seem  that  the
ulmonary  lesions  could  have  changed  before  the  biopsy.
he  thoracic  CT-scan  is  also  used  to  guide  the  procedure.
he  trajectory  of  the  puncture  must  be  as  short  as  possible
nd  avoid  crossing  ﬁssures,  emphysema  bubbles,  bronchial
ubes  and  blood  vessels.  The  internal  thoracic  vessels  must
e  located  and  avoided  in  anterior  approaches.  The  posi-
ion  of  the  patient  in  the  CT-scan  should  be  adjusted  to
he  approach:  procubitus  for  posterior  approaches,  decubi-
us  for  anterior  approaches  and  lateral  decubitus  for  lateral
pproaches.
It  is  preferable  to  biopsy  masses  and  nodules  rather  than
onsolidations  (Fig.  3).  Lung  biopsies  are  in  fact  more  effec-
ive  in  the  nodules  (57%)  and  masses  (71%)  than  in  the
onsolidations  (50%)  [12]. The  poor  performance  of  biop-
ies  in  consolidations  is  due  on  one  hand  to  the  aetiologies
esponsible  for  consolidations  and  on  the  other  hand,  to  the
hysiology  of  the  lung.  Consolidations  are  a  type  of  presen-
ation  that  is  commonly  found  in  infections.  However,  the
ositive  diagnosis  of  infection  is  more  complex  than  that  of
umours  due  to  the  limited  performance  of  bacterial  culture,
hich  depends  on  the  entire  chain  of  events:  the  PLB,  the
ype  of  conditioning,  the  duration  of  transport  and  the  cul-
uring  process.  Certain  teams  propose  culturing  immediately
fter  sampling,  but  the  strictly  aseptic  conditions  necessary
t  the  time  of  culture  limit  the  use  of  this  method.  The  radio-
ogical  semiology  explained  by  the  physiology  of  the  lung
akes  the  biopsy  more  complex.  The  areas  of  consolidation
 diagnose organized pneumopathy in a 65-year-old patient being
 by percutaneous lung biopsy in a 63-year-old patient being treated
 of the alveolar consolidation of the patient in (a) is theoretically
n the patient in (a) is higher, as the lesion is located less than 2 cm
he same for consolidation as for a mass.
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Figure 4. Diffusion MRI (a) and high resolution chest CT-scan (b) centred on an area of alveolar consolidation in a patient being treated for
B lymphoma with abdominal large B cell lymphoma. The diffusion MRI shows a restriction of the diffusion in the posterior external portion of
the lesion and indicates that the internal portion is an atelectasis. The targeted biopsy on the external portion made it possible to discover
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Npulmonary damage from the lymphoma.
on  the  CT-scan  are  in  fact  made  up  of  an  infectious  or
tumoural  area  and  a  peripheral  region  of  reactive  inﬂamma-
tory  tissue  or  atelectasis.  The  limit  between  these  different
entities  is  usually  not  visible  and  many  puncture  are  nega-
tives  because  they  are  made  in  the  atelectasis.  It  is  possible
to  use  a  PET-scan  for  assistance  in  guiding  the  biopsy  in  the
hyper-ﬁxing  pathological  area  [13—15]. However,  a  PET-scan
is  not  always  available  before  biopsy.  Qi  et  al.  propose  dis-
tinguishing  between  pathological  areas  that  have  restricted
diffusion  on  the  MRI  and  areas  of  atelectasis  characterised
by  free  diffusion  (Fig.  4)  [16]. Finally,  for  Hur  et  al.,  the  over-
all  sensitivity  and  the  precision  of  the  PLB  in  lesions  with  a
ground-glass  appearance  are  71%  and  82%,  respectively  [17].
The  precision  of  the  diagnosis  depends  on  the  size  of  the
lesion  [18,19].  It  is  preferable  to  aim  for  voluminous  lesions
to  improve  the  diagnostic  performance  [18—23]. However,
certain  operators  ﬁnd  no  signiﬁcant  difference  in  terms  of
diagnostic  performance  between  lesions  superior  and  infe-
rior  to  2  cm  in  diameter  (Fig.  5)  [24,25].  The  precision  and
sensitivity  of  the  CT-guided  PLB  for  large  nodules  (>  15  mm)
are  91%  and  94%,  respectively,  while  the  precision  and  sensi-
tivity  decrease  for  small  nodules  (<  10  mm)  to  88%  and  82%,
respectively  [26]. When  the  target  is  smaller  than  the  samp-
ling  window  (20  mm),  a  puncture  trajectory  that  makes  it
possible  to  sample  the  largest  amount  of  abnormal  tissue
should  be  used.  A  biopsy  trajectory  parallel  to  the  largest
axis  of  the  target  should  therefore  be  favoured  in  order  to
place  the  largest  possible  part  of  the  sampling  window  in  the
pathological  tissue  and  reduce  as  much  as  possible  the  tak-
ing  of  healthy  tissue  that  has  no  diagnostic  interest  located
around  the  target.  During  the  biopsy,  it  is  useful  to  con-
trol  the  position  of  the  sampling  window  compared  to  the
target  with  scan  cuts  without  injection.  The  control  cuts
make  it  possible  to  position  things  so  that  the  target  is  at  the
T
f
bentre  of  the  sampling  window  in  order  to  sample  the  most
athological  tissue  possible  (Fig.  6).  In  the  same  way,  the
iagnostic  precision  is  better  for  short  puncture  trajecto-
ies  (90%  if  the  trajectory  is  less  than  40  mm)  than  for  long
rajectories  (56%  if  the  trajectory  is  greater  than  40  mm)
Fig.  6)  [26].
In cases  of  infectious  multifocal  pulmonary  lesions,
icro-abscesses  are  often  found  in  other  organs  such  as  the
iver  or  the  spleen.  Targeted  liver  biopsy  on  micro-abscesses
an  be  an  interesting  alternative  to  PLB  that  is  still  effective
n  infra-centimetric  nodules  (Fig.  7).  The  diagnostic  perfor-
ance  of  liver  biopsies  to  screen  for  infection  is  comparable
o  that  of  lung  biopsies  [27].
uantity of sampled material
alibre of the guns
natomical  pathologists  are  more  efﬁcient  when  they  inter-
ret  samples  taken  with  an  18-gauge  (diameter  =  1.2  mm)
un  than  with  a  20-gauge  (diameter  =  0.8  mm)  gun  [28]. They
btain  approximately  two  times  more  material  per  core  sam-
le  with  the  18  G  than  with  the  20  G.  The  overall  diagnostic
recision  of  the  biopsies  is  96%  with  needles  with  a  calibre  of
8  G  and  92%  with  needles  with  a  calibre  of  19  G,  with  sen-
itivities  of  95%  and  89%  and  speciﬁcities  of  100%  and  99%,
espectively  [29].
umber of sampleso  our  knowledge,  there  are  no  particular  recommendations
or  the  number  of  samples  to  be  taken  during  PLBs  in  patients
eing  treated  for  haematological  malignancies.  In  our
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Figure 5. Biopsy of a centimetric nodule of the lower right lobe in a patient being followed for non-Hodgkin’s lymphoma. The lung biopsy
revealed metastasis of the melanoma. The precision and sensitivity of the CT-guided PLB for small nodules (less than 10 mm)  is estimated
to be 88% and 82%, respectively. This performance is theoretically not as good for larger nodules (greater than 15 mm)  with precision and
s ure g
o ncrea
e
t
l
f
f
c
d
s
d
s
o
m
a
i
ﬁ
b
l
s
p
l
f
d
m
g
d
b
s
s
p
[
C
T
b
s
m
censitivity of 91% and 94%, respectively. The trajectory of the punct
f the puncture greater than 2 cm and the small size of the lesion i
xperience,  it  appears  that  the  optimal  number  of  samples
o  be  taken  is  between  three  and  four  (personal  non  pub-
ished  data).  The  increase  in  the  number  of  samples  beyond
our  does  not  increase  diagnostic  performance.  It  is  there-
ore  important  to  deﬁne  the  diagnostic  hypotheses  with  the
linical  practitioner  and  to  agree  on  two  or  three  differential
iagnoses  that  are  to  be  favoured.  In  this  way,  if  there  is  a
uspected  fungal  infection  in  an  immune  depressed  subject
uring  treatment  for  a  haematological  malignancy,  a  ﬁrst
ample  must  be  placed  in  a  dry  tube  and  quickly  cultured  in
rder  to  conﬁrm  colonisation.  The  presence  of  fungal  ﬁla-
ents  can  also  be  found  in  histological  cuts,  which  requires
 second  sample  to  be  ﬁxed  and  stained  (Grocott).  The
nvasive  character  of  a  fungal  infection  is  conﬁrmed  in  the
xed  samples  [30—32]. A  third  sample  must  systematically
e  ﬁxed  in  the  AFA  and  stained  with  HES  to  rule  out  a  speciﬁc
esion  of  the  haematological  disease.  Finally,  a  fourth  frozen
ample  is  recommended  in  our  example.  This  frozen  sam-
le  will  be  absolutely  necessary  if  there  is  a  haematological
esion  for  the  characterisation  of  the  disease  (lymphoma,
or  example)  or  could  be  used  in  histology  or  bacteriology
epending  on  the  needs  (Fig.  8).  During  the  biopsy,  samples
T
f
p
ireater than 4 cm reduces the precision of the biopsy. The trajectory
ses the risk of alveolar bleeding during the biopsy.
ust  be  taken  using  the  sextant  technique  by  inclining  the
un  in  the  target  before  pushing  the  trigger  in  a  different
irection  for  each  sample  so  as  not  to  biopsy  the  cavity  left
y  the  preceding  biopsies.  The  quality  of  the  biopsy  core
amples  is  improved  when  the  tissue  is  pushed  down  in  the
ample  window  before  selecting  it.  To  do  this,  the  gun  sim-
ly  needs  to  be  inclined  again  by  approximately  10  degrees
15].
omplications
he  complications  occurring  during  lung  biopsies  in  patients
eing  treated  for  a  haematological  disease  are  largely  the
ame  as  in  the  general  population,  though  these  patients
ore  often  have  hemostasis  disorders.  The  operators  must
heck  their  practice  and  calculate  the  rate  of  complications.
he  risks  should  be  clearly  explained  to  the  patients  in  order
or  them  to  be  able  to  give  their  informed  consent  before  the
rocedure.  The  complication  rates  of  lung  biopsies  accepted
n  the  literature  are,  for  example,  20.5%  of  pneumothorax,
CT-guided  biopsies  in  lung  infections  
Figure 6. Biopsy of a centimetric nodule of the lower left lobe
in a patient being followed for non-Hodgkin’s lymphoma. The lung
biopsy revealed a bronchial adenocarcinoma. The control cuts made
it possible to get into a position so that the target is at the centre
of the sampling window in order to take the most abnormal tissue
possible.
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Figure 7. Infection caused by Geotrichum clavatum diagnosed via ult
acute myeloid leukaemia. In cases of infectious lesions with hematogen
than the lungs, such as the liver or the spleen. The targeted liver bio
percutaneous lung biopsy that is less efﬁcient on infra-centimetric nodu209
.1%  of  which  require  the  insertion  of  a  thoracic  drain,  and
.3%  of  hemoptysis.
erious complications
he  risk  of  death  caused  by  lung  biopsy  is  exceptional
<  0.15%)  [33]. Serious  complications  requiring  a  speciﬁc
reatment  are  rare  and  include  drained  pneumothorax,
aemopericardium,  hemothorax,  hemoptysis  and  intense
ain  [4,34—36].  The  rates  of  the  main  complications  are
ummarized  in  Table  1.  The  rate  of  complications  during  PLB
oes  not  depend  on  the  appearance  of  the  lesion  on  the  scan
12].
neumothorax
he  insertion  of  a thoracic  drain  to  treat  iatrogenic  pneu-
othorax  occurs  in  3  to  15%  of  all  biopsies  [25]. The  risk
enerally  occurs  for  lesions  located  less  than  2  cm  from  the
leural  cavity  [37]. In  the  majority  of  cases,  the  thoracic
rain  can  be  withdrawn  within  48  h.  When  the  pulmonary
arenchyma  is  destroyed  (emphysema,  GVH  lesions,  etc.),
he  thoracic  drain  can  be  left  in  place  for  a  longer  period  of
ime.
rasound-guided liver biopsy in a febrile patient being treated for
ic dissemination, micro-abscesses are often found in other organs
psy of the micro-abscesses can be an interesting alternative to
les.
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Figure 8. Percutaneous lung biopsy in a 73-year-old patient treated for lymphoplasmocytary non-Hodgkin’s lymphoma in 2002, and
secondary myelodysplasia in 2010 with pancytopoenia (30,000 platelets). The nodules with a ground-glass halo and the clinical history are
suggestive of fungal infection, bacterial infection or progression of the lymphoma. Three samples were taken: the sample ﬁxed in AFA and
the freezing made it possible to establish EBV-induced lymphoproliferation conﬁrmed by EBV PCR measured at 7.07 log.
CT-guided  biopsies  in  lung  infections  211
Table  1  Complication  CT-scan  guided  percutaneous  lung  biopsies  in  the  general  population.
Risk  (%)  Number  of  procedures  Calibre  Ref.
Pneumothorax  (total/chest  tube)  23/5  660  19G  CNB  [51]
62/31  61  18G  PNAB  [26]
28/2.5  162  22G  PNAB  [19]
26/8  846  19G  PNAB  [29]
21/2 97  19G  PNAB  [8]
17/2 135 17G  CNB [37]
17/0.5 605 19G  CNB [52]
Bleeding  (total/haemoptysis)
30/4 660  19G  CNB  [51]
-/2  846  19G  PNAB  [29]
27/6  135  17G  CNB  [37]
20/3.8  604  19G  CNB  [52]
Vasovagal  syncope  0.3  846  19G  PNAB  [29]
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Alveolar  bleeding  is  observed  in  5  to  30%  of  patients  and
haemoptysis  in  between  1.25  and  5%  of  cases  [33,38].  The
depth  of  the  lesion  (>  2  cm  from  the  pleural  cavity)  has  been
identiﬁed  as  the  most  important  risk  factor  for  alveolar
bleeding  [39]. The  hemothorax  rate  is  low  and  is  estimated
to  be  1.5%.  Haemothorax  can  result  from  the  accidental
puncture  of  the  internal  thoracic  or  intercostal  blood  vessels
[40]. The  rate  of  complications  during  PLB  does  not  increase
in  patients  with  thrombocytopoenia  [41].
Pain
Pain  is  a  rare  complication  (0.3%  of  patients)  and  can  occur
despite  local  anaesthesia  without  any  cause  being  identiﬁed
[29].  The  pain  can  be  accompanied  by  vasovagal  syncope,
a  desaturation  in  oxygen  or  a  drop  in  blood  pressure.  All  of
these  symptoms  generally  regress  spontaneously.  However,
this  acute  pain  should  result  in  screening  for  a  complication
and  requires  monitoring.  Therefore,  after  the  procedure,
the  patients  are  generally  monitored  in  the  day  hospital  for
a  few  hours.
Minor complications
Minor  complications  are  common  (30  to  60%)  of  proce-
dures  and  include  pneumothorax  of  low  abundance  (17  to
60%)  and  alveolar  bleeding  (5  to  30%)  [37]. Generally,  these
complications  are  asymptomatic  and  regress  spontaneously.
The  risk  of  pneumothorax  or  bleeding  increases  with  tar-
gets  of  less  than  2  cm.  The  risk  of  pneumothorax  increases
for  peripheral  lesions  located  less  than  2  cm  from  the  chest
wall  (Fig.  9).  Long  trajectories  for  intra-pulmonary  punc-
tures  (>  4  cm)  are  also  associated  with  a  larger  number  of
cases  of  alveolar  bleeding  and  pneumothorax.  The  risk  of
bleeding  and  pneumothorax  also  increases  with  the  pleu-
ral  cavity  is  crossed  several  times  during  the  puncture.  The
duration  of  the  procedure  must  also  be  as  short  as  possible
in  order  to  reduce  the  rate  of  pneumothorax  [37].
t
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serformance
he  number  of  lung  biopsies  has  increased  considerably  over
he  course  of  the  last  decade.  Several  large  studies  have
hown  that  the  sensitivity  and  precision  of  PLB  were  greater
han  80%  (Table  2).  The  rate  of  false  positives  is  generally
ess  than  1%  [42,43]  and  the  rate  of  false  negatives  is  less
han  5  to  10%  [44—46].
Lung  biopsy  makes  it  possible  to  diagnose  up  to  70%  of
nfections  with  a  sensitivity  of  70%  and  a  positive  predic-
ive  value  of  100%  [47,48].  Lung  biopsy  is  more  effective  for
acterial  infections  (100%)  than  for  fungal  infections  (30  to
0%).  The  usual  techniques  such  as  thoracic  CT-scan,  BAL
nd  cultures  rarely  make  it  possible  to  establish  a  diagno-
is  of  fungal  infection.  BAL  is  usually  carried  out  in  patients
ith  neutropoenia  if  the  imaging  suggests  a fungal  infec-
ion,  but  this  method  has  a  sensitivity  of  50%  for  aspergillosis
30—32].  Endoscopic  procedures  can  detect  a  colonisation,
ut  cannot  demonstrate  the  invasive  nature  of  the  infection.
ransbronchial  biopsies,  carried  out  when  the  platelet  count
s  greater  than  50  ×  109/L  only  slightly  improve  the  preci-
ion  of  the  diagnosis  compared  to  exploratory  ﬁbroscopy
ithout  biopsy  [30]. The  histological  results  are  often  more
ffective  than  cultures  for  the  diagnosis  of  bacterial  and
ungal  infections.  Cultures  are  positive  in  less  than  40%
f  patients  with  aspergillosis  or  a  mucormycosis  [48]. The
ultures  are  negative  or  late,  particularly  in  patients  with
eutropoenia  due  to  an  empirical  antibacterial  or  antifun-
al  treatment  administered  before  the  biopsy  [49]. False
ositives  for  fungal  or  bacterial  infection  are  also  possible
ith  cultures.  Aspergillus  is  a  common  saprophyte  and  a  pos-
tive  culture  is  not  proof  of  an  infection.  The  diagnosis  is
herefore  based  on  the  demonstration  of  histological  signs
f  tissue  invasion.  The  biopsy  makes  it  possible  to  distinguish
spergillosis  and  mucormycosis.  This  histological  distinction
s  very  important,  as  mucorales  are  generally  resistant  to
zole  derivatives  and  echinocandins,  so  that  only  ampho-
ericin  B  can  be  used  as  treatment  or  secondary  prophylaxis
uring  transplants  (Fig.  10).  In  addition,  the  histological
esults  allow  for  an  immediate  diagnosis  by  showing  necro-
is  containing  numerous  ﬁlamental  fungi  in  case  of  fungal
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Figure 9. Complicated percutaneous lung biopsies. a, c: in a 32-year-old patient, allografted for acute leukaemia. The lesion is located
less than 10 mm from the pleural cavity. The biopsy was complicated by minimal asymptomatic pneumothorax. The biopsy reveals organized
pneumopathy; b, d: in a 54-year-old patient being treated for chronic lymphoid leukaemia with an indeterminate centimetric nodule of
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The right upper lobe. The biopsy was complicated by asymptomati
esion. The biopsy showed tuberculosis.
nfection.  If  there  is  a  bacterial  infection,  the  histology
hows  granulomas  and  inﬁltrates  composed  of  neutrophil
ranulocytes  or  histiocytes.
CT-scan  guided  PLB  is  a  reliable  method  for  distinguishing
alignant  lesions  of  pulmonary  infections.  The  diagnostic
erformance  is  well  documented,  with  precision  greater
i
b
m
1
Table  2  Performance  of  CT-scan  guided  percutaneous  lung  bi
Sensitivity  (%)  Precision  (
Total 82  88  
87  77  
91  94  
Cancers  89  91  
<  10  mm  88  92  
<  10  mm 67  80  
<  15  mm 72 74 
>  15  mm 94 96
>  20  mm 75 88 
Infections
Fungal  70.6  76.4  olar bleeding concerning the puncture trajectory and around the
han  93%  [21,50]  and  sensitivity  greater  than  95%  [25,34,50].
he  diagnosis  of  lymphoma  is  generally  established  by  biopsy
n  90%  of  patients.  In  cases  of  primary  cancer  in  patients
eing  treated  for  haematological  malignancies,  the  PLB
akes  it  possible  to  establish  the  diagnosis  nine  times  out  of
0  [29]. False  negatives  are  generally  explained  by  samples
opsies  in  the  general  population.
%)  Number  of  procedures  Ref.
61  [26]
162  [19]
846  [29]
604  [52]
47  [26]
10  [17]
70  [8]
27 [8]
8  [17]
17  [31]
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Figure 10. Percutaneous lung biopsy in a patient being treated for acute myeloblastic leukaemia with febrile neutropoenia. a: suspicion of
aspergillosis on the high resolution lung CT-scan performed in January 2007; b: the control scan after 1 month of treatment with voriconazole
showed an unfavourable course. The clinical practitioner then suspected progression of the haemopathy, fungal infection and a bacterial
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Rinfection. Three samples were taken: the sample ﬁxed in AFA and 
infection. The freezing was carried out for the characterisation of a
taken  in  zones  of  inﬂammatory  reorganization  or  necrosis.
The  biopsies  also  make  it  possible  to  diagnose  organized
pneumopathy,  GVH  and  benign  tumours.
PLB  seems  to  have  a  beneﬁt  in  patients  who  are  severely
immune  depressed,  but  the  rate  of  precise  diagnoses  is  gen-
erally  lower  in  immune  depressed  patients  (40%)  than  in  the
immune  competent  group  (90%).  Missed  diagnoses  are  gen-
erally  fungal  infections  conﬁrmed  later  on.  However,  PLB
appears  to  contribute  in  half  of  these  patients  and  gener-
ally  shows  an  infection.  The  other  diagnoses  include  GVH,
organized  pneumonia  and  lymphoma.
Conclusion
CT-scan  guided  percutaneous  lung  biopsies  in  patients  being
treated  for  haematological  malignancies  are  useful  for
the  diagnosis  of  pulmonary  infection  and  make  it  possi-
ble  to  rule  out  a  malignant  tumoural  lesion  with  great
precision.  The  performance  of  the  percutaneous  lung  biop-
sies  is  related  to  the  size  and  the  appearance  of  the
lesion  as  well  as  the  calibre  of  the  samples.  The  risks  ofultures made it possible to establish a diagnosis of mucormycosis
mphoma.
ercutaneous  lung  biopsy  are  limited  and  the  complications
re  generally  benign,  including  alveolar  bleeding  and  pneu-
othorax.  These  complications  are  associated  with  the
ize  of  the  lesion  and  the  depth.  The  discussion  between
he  haematologist,  pneumologists,  pathologist  and  interven-
ional  radiologist  is  essential  to  establish  the  indications  for
he  biopsy,  select  the  best  target  and  deﬁne  the  diagnostic
ypotheses.
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